Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Oral time-limited duvelisib/venetoclax in R/R CLL

Matthew Davids • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia Duvelisib Venetoclax

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase I trial (NCT03534323) assessing duvelisib in combination with venetoclax as a possible treatment for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Early efficacy data for this 1-year time-limited, all oral regimen are promising. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Matthew Davids

Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL 1:21
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 8 Dec 2025
Fixed-duration and MRD-adapted therapy in CLL: insights from ASH 2025 2:08
Fixed-duration and MRD-adapted therapy in CLL: insights from ASH 2025
Matthew Davids • 8 Dec 2025
Mutation-guided finite-duration AV after first-line BTKi+ven-based therapy in CLL/SLL: MAVRiC trial 1:27
Mutation-guided finite-duration AV after first-line BTKi+ven-based therapy in CLL/SLL: MAVRiC trial
Matthew Davids • 8 Dec 2025
Strategies being explored for the potential management of monoclonal B-cell lymphocytosis 0:47
Strategies being explored for the potential management of monoclonal B-cell lymphocytosis
Matthew Davids • 13 Sep 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals